Low Libido Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Low libido — a persistent or recurrent reduction in sexual desire causing personal distress — is one of the most common sexual health complaints encountered in clinical practice. When it causes significant distress and is not better explained by another medical condition, relationship problem, or medication side effect, it meets the diagnostic criteria for a recognised medical disorder.

The current diagnostic framework (DSM-5, 2013) defines:

• Female Sexual Interest/Arousal Disorder (FSIAD): Absence or significant reduction in sexual interest or arousal, causing clinically significant distress, present for ≥6 months. FSIAD subsumes the older DSM-IV-TR diagnosis of Hypoactive Sexual Desire Disorder (HSDD), which remains widely used in research and clinical practice.
• Male Hypoactive Sexual Desire Disorder (MHSDD): Persistently or recurrently deficient or absent sexual/erotic thoughts, fantasies, and desire for sexual activity, causing distress.

Low libido follows a biopsychosocial model: it arises from the interaction of biological factors (hormonal, neurological, medical), psychological factors (depression, anxiety, past trauma, body image), and social/relational factors (relationship conflict, partner sexual dysfunction, life stress). Effective treatment therefore requires comprehensive assessment across all three domains.

Prevalence is substantial: approximately 10% of premenopausal women and up to 40% of postmenopausal women report low sexual desire causing personal distress. In men, prevalence increases with age, comorbid depression, and hypogonadism.

Accurate identification of the underlying cause guides appropriate treatment selection:

Women: HSDD / FSIAD

• Premenopausal HSDD: Often multifactorial. Hormonal contributors include relative androgen insufficiency (low free testosterone), undiagnosed hypothyroidism, and hyperprolactinaemia (pituitary adenoma). Psychological contributors include depression, generalised anxiety, unresolved sexual trauma, and performance anxiety.
• Postmenopausal low libido: Oestrogen and androgen (testosterone, DHEA) deficiency compound each other. Genitourinary syndrome of menopause (GSM — vaginal dryness, dyspareunia) contributes to desire loss through pain avoidance. Testosterone levels in women decline by approximately 50% between ages 20 and 45, independent of menopause.
• Medication-induced low libido: SSRIs and SNRIs (all classes impair desire and orgasm), combined oral contraceptives (increase SHBG, reducing free testosterone), antipsychotics (hyperprolactinaemia), antiandrogens (spironolactone, finasteride, GnRH agonists), and opioids.

Men: Low Testosterone and Hypogonadism

• Primary hypogonadism (testicular failure): Klinefelter syndrome (47,XXY), orchitis, testicular trauma or torsion, chemotherapy/radiotherapy-induced testicular damage.
• Secondary hypogonadism (hypothalamic-pituitary failure): Hyperprolactinaemia (pituitary adenoma), haemochromatosis, Kallmann syndrome, acquired pituitary tumours, use of exogenous anabolic steroids (suppresses endogenous LH/FSH production via negative feedback).
• Late-onset hypogonadism (LOH): Age-related decline in testosterone ('andropause'). Testosterone declines approximately 1–2% per year after age 30. NICE 2017 and EAU 2023 guidelines define symptomatic hypogonadism requiring treatment as morning total testosterone consistently <8 nmol/L (231 ng/dL) or free testosterone <225 pmol/L with symptoms.
• Psychological causes in men: Depression is both a cause and consequence of low libido. Relationship conflict, performance anxiety, pornography-induced desire disorder, and work stress are major non-hormonal contributors.

Shared Causes (Both Sexes)

• Depression and antidepressant use
• Hypothyroidism and hyperthyroidism
• Chronic illness (cardiovascular disease, diabetes, chronic kidney disease, cancer)
• Obstructive sleep apnoea (reduces testosterone and libido in both sexes)
• Alcohol and recreational drug misuse
• Relationship difficulties and partner sexual dysfunction

A structured assessment is required to distinguish primary HSDD/MHSDD from secondary causes that have specific treatments:

Clinical History

• Duration of low libido, onset (gradual vs acute), and relationship to life events, medications, or health changes
• Relationship quality, partner sexual function, history of sexual trauma
• Psychiatric history: depression screening (PHQ-9), anxiety screening (GAD-7)
• Medication review (SSRIs, OCPs, antipsychotics, opioids, finasteride)
• Menstrual history (women): regularity, menopausal symptoms, GSM symptoms (dyspareunia, dryness)

Hormonal Blood Tests

• Oestradiol (E2): Marker of ovarian function and menopausal status; low in menopause and after oophorectomy
• FSH: Elevated FSH (>25 IU/L) confirms ovarian failure/menopause
• Total testosterone: Best collected as a morning fasting sample (08:00–10:00); peak diurnal level. SHBG must be measured concurrently to calculate free testosterone.
• SHBG (sex hormone-binding globulin): Elevated by OCP, hyperthyroidism, liver disease, ageing; when SHBG is high, total testosterone may be normal but bioavailable (free) testosterone is low.
• Free testosterone: Calculated from total testosterone and SHBG using the Vermeulen equation; more clinically relevant than total testosterone in women and in men with elevated SHBG.
• DHEAS: Adrenal androgen precursor; relevant in women with suspected adrenal insufficiency
• Prolactin: Elevated prolactin (hyperprolactinaemia) suppresses GnRH and reduces libido in both sexes; pituitary MRI is indicated if prolactin >1,000 mIU/L.
• TSH: Both hypothyroidism and hyperthyroidism cause libido changes; easily treated when identified
• LH and FSH (in men): Differentiates primary (low T, high LH/FSH) from secondary (low T, low/normal LH/FSH) hypogonadism, guiding treatment choice (TRT vs gonadotrophin stimulation)

Treatment is selected based on the identified cause, sex, menopausal status, and patient preference. Multiple modalities are often combined.

Pharmacological Treatments for Women

1. Flibanserin (Addyi)

• Mechanism: Serotonin 1A agonist and 5-HT2A antagonist; modulates central neurotransmitter balance (reduces serotonin, increases dopamine and noradrenaline in prefrontal cortex). Described as a 'non-hormonal' CNS approach to HSDD.
• FDA approval: Approved August 2015 for premenopausal women with acquired, generalised HSDD. Not approved for postmenopausal women or men.
• BEGONIA trial (Katz et al., 2013, J Sex Med): Phase 3 RCT demonstrating flibanserin increased satisfying sexual events (SSEs) by 0.5–1.0 per month and reduced distress vs placebo. Effect size is modest.
• Dose: 100 mg orally at bedtime (bedtime dosing reduces daytime sedation and dizziness).
• Critical safety alert: Alcohol is absolutely contraindicated with flibanserin — combining them causes severe hypotension and syncope. A REMS (Risk Evaluation and Mitigation Strategy) programme is required by the FDA: prescribers and pharmacists must be certified, and patients must acknowledge alcohol abstinence.
• Side effects: Dizziness (11%), somnolence (11%), nausea (10%), fatigue. CYP3A4 inhibitors (fluconazole, grapefruit juice) dramatically increase flibanserin plasma levels and must be avoided.

2. Bremelanotide (Vyleesi)

• Mechanism: Melanocortin 4 (MC4R) receptor agonist administered as a subcutaneous auto-injector pen 45 minutes before anticipated sexual activity. MC4R activation increases sexual desire via hypothalamic pathways.
• FDA approval: Approved June 2019 for premenopausal women with HSDD. On-demand dosing (not daily); maximum 1 dose per 24 hours, 8 doses per month.
• Efficacy: RECONNECT trials showed statistically significant increase in SSEs and reduction in distress vs placebo; effect size similar to flibanserin.
• Side effects: Nausea (40%, often requiring antiemetic premedication with ondansetron), flushing, transient hypertension (mean increase of 6 mmHg SBP; resolves within 12 hours), headache, injection site reactions. Contraindicated in cardiovascular disease due to transient blood pressure elevation.

3. Testosterone for Women with FSIAD

• The International Society for the Study of Women's Sexual Health (ISSWSH) and IMSAD (International Menopause Society and Androgen Deficiency) Position Statement (2019, J Sex Med) supports testosterone therapy for postmenopausal women with FSIAD when other causes have been excluded.
• No female-specific testosterone preparation is currently FDA-approved, so prescribing is off-label, typically using compounded transdermal testosterone cream (1%) or male transdermal gel (AndroGel 1% at a fraction of the male dose, approximately 5–10 mg/day).
• Target range: Serum total testosterone in the upper quartile of the normal premenopausal female range (1.0–2.5 nmol/L; 28–72 ng/dL); avoid supraphysiological levels.
• Monitoring: Testosterone and SHBG at 3–6 months; watch for androgenic side effects (acne, hirsutism, clitoromegaly at supraphysiological doses).
• Duration: Trial for 3–6 months; if no improvement in desire and distress, discontinue.

4. Oestrogen and Genitourinary Syndrome of Menopause (GSM)

• Local vaginal oestrogen (Vagifem pessaries, Estring ring, Ovestin cream) relieves vaginal dryness and dyspareunia, removing a major barrier to sexual desire in postmenopausal women. Minimal systemic absorption; safe in most patients including those with oestrogen-sensitive cancers (low-dose vaginal oestrogen).
• Ospemifene (Osphena): oral SERM approved for dyspareunia in postmenopausal women; also improves vaginal health without systemic oestrogen effects.
• DHEA vaginal suppository (Intrarosa, prasterone): converts locally to oestrogen and testosterone; approved for dyspareunia in postmenopausal women.

Pharmacological Treatments for Men

Testosterone Replacement Therapy (TRT)

• Indicated in men with symptomatic hypogonadism: morning total testosterone consistently below the reference range on two separate measurements, with symptoms (low libido, fatigue, erectile dysfunction, decreased mood, reduced muscle mass).
• NICE 2017 and EAU 2023 criteria: Total testosterone <8 nmol/L (231 ng/dL) warrants treatment; 8–12 nmol/L is a grey zone where treatment may be considered if symptoms are present and other causes excluded; >12 nmol/L generally does not support TRT for low libido.
• TRT formulations:
  • Transdermal gel (Testogel, AndroGel, Tostran): Daily application to skin; mimics physiological diurnal variation; avoids injection peaks/troughs. Transfer to female partners is a concern.
  • Intramuscular injection (testosterone cypionate 200 mg every 2 weeks, or testosterone enanthate every 2–3 weeks; Nebido [testosterone undecanoate] 1,000 mg every 10–14 weeks): Convenient for some patients; Nebido provides the most stable levels.
  • Subcutaneous pellet (Testopel): Implanted under the skin every 3–6 months; steady-state levels but irreversible until pellet dissolves.
  • Buccal tablet (Striant): Twice-daily buccal application; less commonly used.
• Monitoring: Haematocrit (polycythaemia risk — TRT stimulates erythropoiesis), PSA (rule out prostate cancer exacerbation), total testosterone trough level at 6 months, then annually.
• Contraindications to TRT: Active prostate cancer or breast cancer, haematocrit >54%, untreated severe sleep apnoea, uncontrolled heart failure.
• Fertility consideration: TRT suppresses endogenous LH/FSH via negative feedback, causing testicular atrophy and azoospermia. Men wishing to preserve fertility should use gonadotrophin stimulation (hCG ± FSH) instead of exogenous testosterone.

Psychosexual and Psychological Therapies

• Sensate focus (Masters and Johnson): A structured, progressive couples therapy programme that reduces performance anxiety by initially prohibiting intercourse and focusing on non-demand sensual touch, gradually reintroducing sexual contact as anxiety resolves. Evidence-based for HSDD and female sexual dysfunction.
• Cognitive behavioural therapy (CBT) for sexual dysfunction: Addresses negative cognitions about sex, body image concerns, and avoidance behaviours. May be delivered individually or as couples CBT.
• Mindfulness-based cognitive therapy (MBCT): Lori Brotto's mindfulness-based CBT programme for FSIAD has demonstrated efficacy in RCTs, improving sexual desire and arousal through present-moment awareness during sexual activity.
• Sex therapy / psychosexual counselling: Combines psychoeducation, communication skills training, and tailored exercises. The PLISSIT model (Permission, Limited Information, Specific Suggestions, Intensive Therapy) provides a structured framework.
• Antidepressant management: In patients with SSRI-induced low libido, options include: switching to bupropion (least sexual side effect profile among antidepressants), adding bupropion 150–300 mg/day, switching to mirtazapine, or adding sildenafil/tadalafil in men for SSRI-associated erectile/desire dysfunction.

Effective treatment of low libido provides substantial improvements in sexual health, personal wellbeing, and relationship quality:

• Improved sexual desire: Flibanserin and bremelanotide each produce statistically significant increases in satisfying sexual events (0.5–1.0 additional SSE per month vs placebo in phase 3 trials), alongside reductions in personal distress scores (FSDS-R).
• Testosterone in women: A meta-analysis of 35 RCTs (Islam et al., Lancet Diabetes Endocrinol, 2019) found testosterone significantly improved sexual desire, arousal, orgasm frequency, and responsiveness compared to placebo or oestrogen alone in postmenopausal women, with a standardised mean difference of 0.36 for desire.
• TRT in men: Systematic reviews confirm TRT significantly increases sexual desire, frequency of sexual activity, and erectile function in men with confirmed hypogonadism (total testosterone <8 nmol/L). Benefits for libido appear within 3–6 weeks; maximal effect at 3–6 months.
• Psychosexual therapy: Sensate focus and CBT-based programmes have demonstrated durable improvements in sexual desire, sexual satisfaction, and relationship quality at 6–12 month follow-up in RCTs. Psychosexual therapy is the most sustainable long-term treatment when psychological factors predominate.
• Treatment of GSM: Local vaginal oestrogen resolves dyspareunia in 80–90% of postmenopausal women, removing pain avoidance as a driver of desire loss.
• Quality of life: Sexual satisfaction is a key component of overall wellbeing and relationship satisfaction. Studies consistently show that treatment of low libido improves relationship quality, self-esteem, and mental health outcomes.

Each treatment modality carries specific risks that must be discussed during shared decision-making:

Flibanserin (Addyi) Risks

• Severe hypotension and syncope with alcohol: The most critical safety issue; all patients must abstain from alcohol during flibanserin treatment. The REMS programme mandates patient education on this risk.
• CNS side effects: somnolence (11%), dizziness (11%) — mitigated by bedtime dosing
• Drug interactions: CYP3A4 inhibitors (fluconazole, erythromycin, cimetidine) increase flibanserin exposure dramatically and are contraindicated

Bremelanotide (Vyleesi) Risks

• Nausea (40%): Often severe enough to limit use; antiemetic pretreatment (ondansetron 4 mg) is recommended
• Transient hypertension: Contraindicated in patients with established cardiovascular disease, high cardiovascular risk, or uncontrolled hypertension
• Hyperpigmentation (transient facial flushing)

Testosterone Therapy in Women

• Androgenic side effects (acne, hirsutism, clitoromegaly): rare at physiological doses; require dose reduction or discontinuation if they occur
• Long-term safety: 2019 ISSWSH position statement notes insufficient long-term data on breast cancer, cardiovascular outcomes, and endometrial safety. Short-term trials (<2 years) show no increased risk of breast cancer.

TRT in Men

• Polycythaemia: TRT stimulates erythropoiesis; haematocrit >54% requires dose reduction or phlebotomy (increased thrombotic risk)
• Infertility: TRT suppresses spermatogenesis via negative feedback; azoospermia typically develops within 3–6 months. Reversible in most men within 6–24 months after stopping TRT, but not universally.
• Prostate effects: TRT is contraindicated in active prostate cancer. PSA monitoring is required; TRT does not increase prostate cancer incidence in hypogonadal men but may accelerate undiagnosed disease.
• Cardiovascular risk: Remains an area of research. TRAVERSE trial (2023, NEJM) demonstrated TRT in older men with hypogonadism did not significantly increase major adverse cardiovascular events compared to placebo over ~3 years, though a small increase in atrial fibrillation and pulmonary embolism was noted.
• Testicular atrophy: Suppression of endogenous LH reduces testicular size and testosterone production; hCG co-administration can preserve testicular volume and function

Structured follow-up ensures safety, efficacy assessment, and management of adverse effects:

Women on Flibanserin

• Review at 4–8 weeks: assess for improvement in sexual desire and distress (Female Sexual Function Index [FSFI] or Female Sexual Distress Scale [FSDS-R]), alcohol adherence, side effects
• If no improvement after 8 weeks of consistent use, discontinue — lack of efficacy in the short term is unlikely to resolve with longer treatment
• Annual review for continued treatment

Women on Testosterone

• Serum total testosterone and SHBG at 3 and 6 months; then every 6 months if stable
• Watch for androgenic side effects at each visit (skin, hair pattern)
• FSFI/FSDS-R assessment at 3 and 6 months to confirm clinical response
• If no symptom improvement after 6 months at therapeutic levels, discontinue and reassess

Men on TRT

• Testosterone level (trough or mid-cycle depending on formulation) at 3–6 months after starting; target mid-normal range (12–20 nmol/L for most men)
• Haematocrit at 3–6 months (polycythaemia surveillance)
• PSA at 3–12 months (digital rectal examination if clinically indicated)
• Liver function (orally active 17-alpha-alkylated androgens cause hepatotoxicity; injectable/gel forms do not, but a baseline LFT is standard)
• Bone mineral density (DEXA) at baseline in men with osteoporosis risk factors; TRT improves bone density in hypogonadal men
• Annual reviews thereafter with the above parameters

Psychosexual Therapy

• Typically 6–12 sessions over 3–6 months with a certified sex therapist or clinical psychologist
• Concurrent couples therapy may be recommended when relationship conflict is a significant contributor
• Outcome assessment at session 6 and at end of therapy using validated measures (FSFI, IIEF-15, Patient Global Impression of Change)

Treatment costs for Low Libido Treatment vary significantly by procedure complexity, healthcare system, and geographic location. In India — the leading global medical tourism destination — major procedures cost 60–85% less than comparable treatment in the USA or UK while maintaining equivalent or superior clinical outcomes at NABH- or JCI-accredited facilities. Consultation and diagnostic workup: $30–200 India vs $500–3,000 USA. Inpatient procedures: $1,000–10,000 India vs $10,000–80,000 USA. Medications and ongoing management: generic drugs available in India at 80–95% lower cost than branded equivalents in the USA. Follow-up imaging and laboratory monitoring: 70–85% cost savings in India. Medical tourism packages (including treatment, accommodation, and local logistics support) are offered by major Indian hospital groups (Apollo, Fortis, Medanta, Narayana Health, Manipal Hospitals). For patients from high-income countries, medical tourism to India, Thailand, or Turkey for elective procedures can achieve savings of $10,000–200,000 per episode while accessing care from internationally trained specialists.

Lifestyle modifications and non-pharmacological approaches play an important complementary role in managing low libido:

• Exercise: Regular aerobic exercise (150 minutes/week moderate intensity) increases testosterone in men, improves body image and mood, reduces fatigue, and is associated with improved sexual function across multiple observational studies. Resistance training has an additional positive effect on testosterone in men.
• Sleep optimisation: Obstructive sleep apnoea (OSA) is a significant but often unrecognised cause of low libido in both sexes, via its negative effect on nocturnal testosterone production. Diagnosis with polysomnography and CPAP treatment reliably improves testosterone and sexual desire in men with OSA. Targeting 7–9 hours of quality sleep per night is universally beneficial.
• Alcohol reduction: Chronic alcohol use suppresses testosterone production via direct testicular toxicity and increased oestrogen conversion. Reducing alcohol consumption to within recommended limits (UK: <14 units/week; USA: <2 drinks/day for men, <1 for women) is a straightforward first step.
• Weight management: Obesity is associated with lower testosterone in men (adipose tissue converts testosterone to oestradiol via aromatase). Weight loss of 10% or more significantly increases testosterone levels and improves sexual desire in obese hypogonadal men.
• Relationship communication: Couples who openly discuss sexual preferences, concerns, and unmet needs report higher sexual satisfaction. Structured communication exercises, intimacy-building activities, and reducing performance pressure (sensate focus exercises undertaken independently) can meaningfully improve desire.
• Managing antidepressant side effects: Switching from SSRIs/SNRIs to bupropion (wellbutrin) or mirtazapine, or adding bupropion SR 150 mg to an existing SSRI, can significantly improve sexual desire and orgasmic function without compromising antidepressant efficacy.
• Complementary approaches (limited evidence): Tribulus terrestris, maca root, and ginseng have limited clinical trial evidence for modest improvements in sexual desire. L-arginine (a nitric oxide precursor) may improve arousal in some women. These are not first-line treatments but may be discussed as part of shared decision-making.